Surien Pharmaceuticals Private Limited, a active private limited company, was established on 19 April 2004 in Chennai, Tamil Nadu, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U24232TN2004PTC053031. Registered under ROC Roc Chennai. it is unlisted. It has an authorized capital of ₹5.00 Cr and a paid-up capital of ₹2.16 Cr.
Formerly known as Shince Pharmaceuticals Private Limited. It upholds a compliant status. Its leadership includes Gowri Krishnamoorthy (Director), Ramasamy Krishnamoorthy (Managing Director), Chathurappan Anbazhagan (Whole-Time Director). Past directors included Chathurappan Anbazhagan. It holds ₹20.21 Cr open charges and ₹6.06 Cr settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at 108, Chekkadi Street, Kovur, Chennai, Tamil Nadu, 602101.
U24232TN2004PTC053031
053031
19 April 2004
₹5.00 Cr
₹2.16 Cr
Roc Chennai
Unlisted
Active
Explore comprehensive insights into Surien Pharmaceuticals Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Gowri Krishnamoorthy | Director | 21 Apr 2004 | Current |
| Ramasamy Krishnamoorthy | Managing Director | 21 Apr 2007 | Current |
| Chathurappan Anbazhagan | Whole-Time Director | 11 Oct 2018 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 11 Oct 2018 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Surien Pharmaceuticals Private Limited, for the financial year ended 2024, experienced significant reduction in revenue, with a 38.04% decrease. The company also saw a substantial improvement in profitability, with a 83.66% increase in profit. The company's net worth moved up by a moderate rise of 2.24%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
Unlock access to Surien Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Reveal ownership structures and financial performance - Get instant access now!
₹202,093,000.00
₹60,618,843.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 02 Dec 2023 | Others | ₹5.20 M | Open |
| 22 Sep 2022 | Others | ₹10.77 Cr | Open |
| 04 Sep 2010 | State Bank Of India | ₹8.92 Cr | Open |
| 31 Oct 2016 | Others | ₹1.00 Cr | Satisfied |
| 10 Jan 2009 | Karnataka Bank Limited | ₹1.00 Cr | Satisfied |
Explore comprehensive loan charge details -
Unlock and access historical data on people associated with Surien Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Surien Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Surien Pharmaceuticals's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Surien Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was recorded as a recent event.
Surien Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Chennai. was recorded as a recent event.
Progress on A charge with Others amounted to Rs. 0.52 Cr with Charge ID 100828083 was registered on 02 Dec 2023. was documented.
The activity A charge with Others amounted to Rs. 10.77 Cr with Charge ID 100615448 was registered on 22 Sep 2022. was completed.
Progress on A charge with State Bank Of India of Rs. 8.92 Cr registered on 04 Sep 2010 with Charge ID 10294826 was modified on 31 Dec 2021. was documented.
The activity Chathurappan Anbazhagan was appointed as a Whole-time director was appointed as a Whole-time director on 11 Oct 2018 & has been associated with this company since 7 years 2 months . was completed.
The CIN of Surien Pharmaceuticals Private Limited is U24232TN2004PTC053031.
Surien Pharmaceuticals Private Limited is headquartered at 108, Chekkadi Street, Kovur, Chennai, Tamil Nadu, 602101.
Surien Pharmaceuticals Private Limited was incorporated on 19 April 2004.
The current directors of Surien Pharmaceuticals Private Limited are
The primary industry of Surien Pharmaceuticals Private Limited is Manufacturing.
Surien Pharmaceuticals Private Limited is unlisted.
The authorized capital of Surien Pharmaceuticals Private Limited is ₹5.00 Cr, and the paid-up capital is ₹2.16 Cr.
The compliance status of Surien Pharmaceuticals Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX